{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:34:22Z","timestamp":1789173262931,"version":"build-2803163510"},"reference-count":34,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2022.11305","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T10:55:28Z","timestamp":1649415328000},"source":"Crossref","is-referenced-by-count":10,"title":["Potential role for pentoxifylline as an anti\u2011inflammatory drug for patients with acute coronary syndrome"],"prefix":"10.3892","volume":"23","author":[{"given":"Daniel","family":"Brie","sequence":"first","affiliation":[{"name":"Department of Interventional Cardiology, Cardiovascular Disease Institute Timisoara, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Mornos","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Cardiovascular Disease Institute Timisoara, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diduta","family":"Brie","sequence":"additional","affiliation":[{"name":"Department of Cellular Biology, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Luca","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Cardiovascular Disease Institute Timisoara, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Petrescu","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Cardiovascular Disease Institute Timisoara, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Boruga","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Toxicology and Drug Industry, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"key20220526110329_b1-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/heart.87.3.201","article-title":"Inflammation in acute coronary syndromes","volume":"87","author":"Mulvihill","year":"2002","journal-title":"Heart"},{"key":"key20220526110329_b2-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/2048872612441582","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease","volume":"1","author":"Badimon","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"key20220526110329_b3-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute coronary syndromes: The way forward from mechanisms to precision treatment","volume":"136","author":"Crea","year":"2017","journal-title":"Circulation"},{"issue":"32188","key":"key20220526110329_b4-ETM-0-0-11305","doi-asserted-by":"publisher","DOI":"10.1038\/srep32188","article-title":"Effects of IL-1\u03b2, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity","volume":"6","author":"Bester","year":"2016","journal-title":"Sci Rep"},{"key":"key20220526110329_b5-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/09629350310001633360","article-title":"Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris","volume":"12","author":"Ozeren","year":"2003","journal-title":"Mediators Inflamm"},{"key":"key20220526110329_b6-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1161\/01.cir.99.16.2079","article-title":"Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events","volume":"99","author":"Biasucci","year":"1999","journal-title":"Circulation"},{"key":"key20220526110329_b7-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0002-9149(81)90083-7","article-title":"Unstable angina: Natural history and determinants of prognosis","volume":"48","author":"Mulcahy","year":"1981","journal-title":"Am J Cardiol"},{"key":"key20220526110329_b8-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijcard.2019.03.049","article-title":"Inflammation during acute coronary syndromes-Risk of cardiovascular events and bleeding","volume":"287","author":"Nanchen","year":"2019","journal-title":"Int J Cardiol"},{"key":"key20220526110329_b9-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1161\/01.cir.99.7.855","article-title":"Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability","volume":"99","author":"Biasucci","year":"1999","journal-title":"Circulation"},{"key":"key20220526110329_b10-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1161\/01.cir.98.22.2370","article-title":"Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina","volume":"98","author":"Liuzzo","year":"1998","journal-title":"Circulation"},{"issue":"e000365","key":"key20220526110329_b11-ETM-0-0-11305","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000365","article-title":"Pentoxifylline for vascular health: A brief review of the literature","volume":"3","author":"McCarty","year":"2016","journal-title":"Open Heart"},{"key":"key20220526110329_b12-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1185\/03007998609110431","article-title":"Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease","volume":"10","author":"Perego","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"key20220526110329_b13-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1097\/HJH.0000000000001086","article-title":"Effects of pentoxifylline on inflammatory markers and blood pressure: A systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Brie","year":"2016","journal-title":"J Hypertens"},{"key":"key20220526110329_b14-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jcin.2011.05.016","article-title":"Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel","volume":"4","author":"Ueno","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"key20220526110329_b15-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"ESC Scientific Document Group: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"key20220526110329_b16-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"key20220526110329_b17-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2006.11.032","article-title":"Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo-controlled study","volume":"196","author":"Fernandes","year":"2008","journal-title":"Atherosclerosis"},{"key":"key20220526110329_b18-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/s0003-4975(01)02462-6","article-title":"Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients","volume":"71","author":"Boldt","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"key20220526110329_b19-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.5152\/akd.2014.5883","article-title":"Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to\/less than 30%)","volume":"15","author":"Mansourian","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"key20220526110329_b20-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.cir.0000021599.56755.a1","article-title":"Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study","volume":"106","author":"Altman","year":"2002","journal-title":"Circulation"},{"key":"key20220526110329_b21-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/eurheartj\/ehw207","article-title":"Anti-inflammatory treatment of acute coronary syndromes: The need for precision medicine","volume":"37","author":"Crea","year":"2016","journal-title":"Eur Heart J"},{"key":"key20220526110329_b22-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: Current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"key20220526110329_b23-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"key20220526110329_b24-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"key":"key20220526110329_b25-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"key20220526110329_b26-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"key":"key20220526110329_b27-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/01.CIR.0000087404.53661.F8","article-title":"Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial","volume":"108","author":"Mahaffey","year":"2003","journal-title":"Circulation"},{"key":"key20220526110329_b28-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","article-title":"Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial","volume":"108","author":"Granger","year":"2003","journal-title":"Circulation"},{"key":"key20220526110329_b29-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ahj.2005.06.008","article-title":"Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction","volume":"151","author":"Armstrong","year":"2006","journal-title":"Am Heart J"},{"key":"key20220526110329_b30-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jtcvs.2007.12.062","article-title":"Pexelizumab in ischemic heart disease: A systematic review and meta-analysis on 15,196 patients","volume":"136","author":"Testa","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20220526110329_b31-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"key":"key20220526110329_b32-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"key20220526110329_b33-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome. The Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"key20220526110329_b34-ETM-0-0-11305","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/jcph.926","article-title":"Effect of pentoxifylline in ameliorating myocardial injury in patients with myocardial infarction undergoing thrombolytic therapy: A pilot randomized clinical trial","volume":"57","author":"Namdar","year":"2017","journal-title":"J Clin Pharmacol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:03:39Z","timestamp":1653552219000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2022.11305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,8]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2022.11305","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"article-number":"378"}}